The U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Johnson & Johnson’s SPRAVATO (esketamine) CIII nasal spray, making the treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate response to at least two oral antidepressants. “Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate...